William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
Stocks · News reference
Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy Of Arcus’s Casdatifan; Data Expected to Be Generated By Mid-2027
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target
TD Cowen Initiates Coverage On Arcus Biosciences with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Buy rating.
Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today
Chip stocks sold off after a 5% KOSPI plunge, with Micron and Applied Materials sinking, while J&J fell despite a guidance raise.
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high, with Fed minutes and bond auctions ahead.